Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $23.57.
Several analysts have recently weighed in on CRBU shares. Evercore ISI began coverage on shares of Caribou Biosciences in a research report on Tuesday, October 31st. They set an “outperform” rating and a $13.00 price objective for the company. Cantor Fitzgerald began coverage on Caribou Biosciences in a report on Wednesday, November 8th. They issued a “neutral” rating for the company.
Institutional Investors Weigh In On Caribou Biosciences
Hedge funds have recently made changes to their positions in the company. Avidity Partners Management LP lifted its position in Caribou Biosciences by 119.3% during the third quarter. Avidity Partners Management LP now owns 6,050,212 shares of the company’s stock valued at $28,920,000 after purchasing an additional 3,291,612 shares during the period. BlackRock Inc. lifted its position in shares of Caribou Biosciences by 0.7% during the first quarter. BlackRock Inc. now owns 4,754,563 shares of the company’s stock worth $25,247,000 after purchasing an additional 32,480 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Caribou Biosciences by 49.3% in the third quarter. Vanguard Group Inc. now owns 3,822,151 shares of the company’s stock valued at $18,270,000 after purchasing an additional 1,261,920 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in Caribou Biosciences during the 3rd quarter worth approximately $16,730,000. Finally, State Street Corp lifted its holdings in Caribou Biosciences by 4.9% during the 1st quarter. State Street Corp now owns 3,355,292 shares of the company’s stock worth $17,817,000 after buying an additional 156,399 shares in the last quarter. 59.16% of the stock is currently owned by hedge funds and other institutional investors.
Caribou Biosciences Price Performance
Shares of CRBU stock opened at $5.12 on Monday. Caribou Biosciences has a 1 year low of $3.44 and a 1 year high of $8.59. The firm has a fifty day moving average price of $5.59 and a 200-day moving average price of $5.58. The company has a market cap of $452.77 million, a price-to-earnings ratio of -3.41 and a beta of 2.49.
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last announced its earnings results on Tuesday, November 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.26. The company had revenue of $23.66 million for the quarter, compared to analyst estimates of $3.53 million. Caribou Biosciences had a negative return on equity of 30.33% and a negative net margin of 273.19%. Equities research analysts expect that Caribou Biosciences will post -1.35 EPS for the current year.
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Caribou Biosciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Caribou Biosciences wasn’t on the list.
While Caribou Biosciences currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.